Show simple item record

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae

dc.contributor.authorDiniz, Márcio A.
dc.contributor.authorGresham, Gillian
dc.contributor.authorKim, Sungjin
dc.contributor.authorLuu, Michael
dc.contributor.authorHenry, N. L.
dc.contributor.authorTighiouart, Mourad
dc.contributor.authorYothers, Greg
dc.contributor.authorGanz, Patricia A.
dc.contributor.authorRogatko, André
dc.date.accessioned2022-08-10T18:12:45Z
dc.date.available2022-08-10T18:12:45Z
dc.date.issued2021-11-09
dc.identifier.citationBMC Medical Research Methodology. 2021 Nov 09;21(1):244
dc.identifier.urihttps://doi.org/10.1186/s12874-021-01368-w
dc.identifier.urihttps://hdl.handle.net/2027.42/173584en
dc.description.abstractAbstract Background Graphical displays and data visualization are essential components of statistical analysis that can lead to improved understanding of clinical trial adverse event (AE) data. Correspondence analysis (CA) has been introduced decades ago as a multivariate technique that can communicate AE contingency tables using two-dimensional plots, while quantifying the loss of information as other dimension reduction techniques such as principal components and factor analysis. Methods We propose the application of stacked CA using contribution biplots as a tool to explore differences in AE data among treatments in clinical trials. We defined five levels of refinement for the analysis based on data derived from the Common Terminology Criteria for Adverse Events (CTCAE) grades, domains, terms and their combinations. In addition, we developed a Shiny app built in an R-package, visae, publicly available on Comprehensive R Archive Network (CRAN), to interactively investigate CA configurations based on the contribution to the explained variance and relative frequency of AEs. Data from two randomized controlled trials (RCT) were used to illustrate the proposed methods: NSABP R-04, a neoadjuvant rectal 2 × 2 factorial trial comparing radiation therapy with either capecitabine (Cape) or 5-fluorouracil (5-FU) alone with or without oxaliplatin (Oxa), and NSABP B-35, a double-blind RCT comparing tamoxifen to anastrozole in postmenopausal women with hormone-positive ductal carcinoma in situ. Results In the R04 trial (n = 1308), CA biplots displayed the discrepancies between single agent treatments and their combinations with Oxa at all levels of AE classes, such that these discrepancies were responsible for the largest portion of the explained variability among treatments. In addition, an interaction effect when adding Oxa to Cape/5-FU was identified when the distance between Cape+Oxa and 5-FU + Oxa was observed to be larger than the distance between 5-FU and Cape, with Cape+Oxa and 5-FU + Oxa in different quadrants of the CA biplots. In the B35 trial (n = 3009), CA biplots showed different patterns for non-adherent Anastrozole and Tamoxifen compared with their adherent counterparts. Conclusion CA with contribution biplot is an effective tool that can be used to summarize AE data in a two-dimensional display while minimizing the loss of information and interpretation.
dc.titleVisualizing adverse events in clinical trials using correspondence analysis with R-package visae
dc.typeJournal Article
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173584/1/12874_2021_Article_1368.pdf
dc.identifier.doihttps://dx.doi.org/10.7302/5315
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.date.updated2022-08-10T18:12:44Z
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.